The Puzzle of Perverse Incentives
American healthcare is a weird puzzle for policy wonks: we spend nearly twice as much per capita as other developed nations while our outcomes are pretty mediocre. The usual explanations—administrative bloat, malpractice costs, or Americans’ love affair with expensive gadgets—only tell part of the story. They miss the deeper structural mess underneath. When you really dig into how healthcare policy is designed, what you find is a system where everyone makes perfectly rational decisions that add up to completely irrational results.
Take prescription drug prices. Everyone hates them, politicians promise to fix them, but they stay sky-high. The obvious villain is Big Pharma and their pricing power. But that misses the complicated web of middlemen who actually make money off high list prices. Pharmacy benefit managers, insurance companies, even some patient advocacy groups have figured out ways to profit from the current pricing mess, all while publicly demanding reform.
This is why healthcare policy analysis can’t rely on simple stories about greedy corporations or bumbling government bureaucrats. The system’s dysfunction doesn’t come from individual bad actors. It comes from a complicated architecture of overlapping incentives that reward behaviors which, when you add them all up, work against what we supposedly want: accessible, affordable, quality care.
The Insurance Intermediary Economy
Health insurance companies wear way too many hats in American healthcare. They pool risk, process claims, negotiate networks, and basically regulate care delivery. This pile-up of functions creates what economists call a “moral hazard” problem, but not the way most people think. The moral hazard isn’t mainly about patients overusing care—it’s about insurers having financial reasons to increase total healthcare spending while looking like they’re controlling costs.
The Affordable Care Act requires insurers to spend at least 80% of premium revenue on medical care. Sounds pro-consumer, right? Actually, it creates a backwards incentive: insurers’ absolute dollar profits go up when total medical spending rises, as long as their administrative percentage stays the same. An insurer keeping 20% of $1000 in premiums makes $200. Keep 20% of $1500? That’s $300. The regulation meant to limit insurer profits actually encourages them to let overall spending climb.
You see this playing out in negotiations with healthcare providers and drug companies. Insurers don’t have much reason to drive hard bargains on price when they can just pass increased costs to employers and consumers through higher premiums. The result is managed inflation where everyone except the people actually paying benefits from rising costs. Providers get higher reimbursements, insurers get bigger absolute profits, and pharmacy benefit managers collect percentage-based fees on increasingly expensive drugs.
The political implications are wild. Insurance companies can honestly say they’re fighting high costs while simultaneously benefiting from them. This explains why industry lobbying focuses more on maintaining market structure than on actual price reduction, and why insurance executives can show up at congressional hearings expressing real frustration about drug costs while their companies’ financial interests line up with price increases.
Provider Consolidation and Market Power
Hospital consolidation is another layer of this incentive puzzle. Over the past two decades, hospital systems have gone on aggressive merger sprees, usually justified by claims about better efficiency and care coordination. The economic reality is more complicated: consolidation does cut certain operational costs, but it also dramatically increases market power, letting health systems squeeze higher prices from insurers.
The financial mechanics work differently than in most industries. When hospitals merge, they don’t mainly compete on price because patients rarely choose hospitals based on cost. Instead, consolidated systems use their must-have status with insurers—who need comprehensive provider networks to sell competitive products—to negotiate higher reimbursement rates across everything they do. This market power extends beyond direct hospital care to employed physician practices, outpatient services, and even health insurance products that many large systems now offer.
Federal antitrust enforcement has struggled with healthcare consolidation partly because traditional merger analysis focuses on consumer welfare in terms of direct price and quality effects. But healthcare markets are weird: demand doesn’t respond to price, information is asymmetric, and third-party payment systems hide price signals. A merger that looks competitively neutral under standard analysis can enable coordinated price increases that flow through to employers and employees via higher insurance premiums.
State and federal policymakers face a particular bind here because many hospital systems have become politically powerful economic anchors in their regions. Large health systems often rank among the top employers in their metro areas, making elected officials reluctant to pursue aggressive antitrust enforcement that might threaten local jobs. This political dynamic helps explain why healthcare consolidation has proceeded largely unchecked despite mounting evidence of its role in cost escalation.
The Technology Adoption Paradox
Healthcare technology is perhaps the most backwards aspect of American healthcare economics. While technological advancement cuts costs in most industries, healthcare technology consistently drives spending up. This isn’t because medical technology doesn’t work—quite the opposite. The problem is how payment systems interact with innovation incentives.
Fee-for-service reimbursement models reward providers for using expensive new technologies regardless of their marginal benefit over existing alternatives. A new surgical robot that costs $2 million and allows slightly less invasive procedures generates revenue through higher procedure codes and facility fees, even if patient outcomes improve only a little. The payment system doesn’t distinguish between high-value innovations that dramatically improve outcomes and expensive toys that provide minimal clinical benefit.
This extends to pharmaceutical development, where drug companies rationally focus research and development spending on conditions with generous insurance coverage rather than global health priorities. The result is a steady stream of new cancer drugs that extend life by a few months at costs exceeding $100,000 per year, while research into infectious diseases affecting primarily uninsured populations gets minimal private investment.
Medicare’s role as the largest single payer gives it enormous influence over these technology adoption patterns. When Medicare sets reimbursement rates for new procedures or drugs, private insurers typically follow similar pricing structures. This means Medicare payment policy effectively shapes the direction of medical innovation across the entire healthcare system, often in ways Congress never explicitly intended or debated.
Following the Money Forward
Understanding these incentive structures suggests that effective healthcare reform requires more than addressing individual symptoms like drug pricing or insurance coverage. The challenge is redesigning systems where stakeholder incentives actually line up with societal goals of accessible, affordable, high-quality care. Some promising approaches are emerging—value-based payment models, direct primary care arrangements, and state-level public options—but each faces implementation challenges rooted in the same political economy dynamics that created current problems.
The path forward means acknowledging that healthcare markets will never function like normal consumer goods markets, while recognizing that government regulation alone can’t overcome misaligned private sector incentives. What’s needed is a more sophisticated understanding of how policy design shapes behavior throughout the healthcare ecosystem, from individual clinical decisions to corporate merger strategies.
This analysis raises uncomfortable questions about whether incremental reforms can address systemic dysfunction, or whether more fundamental restructuring is necessary. I’m curious about readers’ experiences navigating these systems—both as patients and professionals—and whether you’ve observed the incentive dynamics described here playing out in your own healthcare encounters.